Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients

Ohashi,Kazuki; Ishikawa,Toru; Suzuki,Mitsuyuki; Abe,Hiroko; Koyama,Fujiko; Nakano,Tomomi; Ueki,Aya; Noguchi,Hirohito; Hasegawa,Erina; Hirosawa,Shiori; Kobayashi,Miki; Hirosawa,Hiroshi; Sato,Kaede; Fukazawa,Takako; Maruyama,Yuka; Yoshida,Toshiaki

doi:10.3892/etm.2017.5488

Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients

Authors:
- Kazuki Ohashi
- Toru Ishikawa
- Mitsuyuki Suzuki
- Hiroko Abe
- Fujiko Koyama
- Tomomi Nakano
- Aya Ueki
- Hirohito Noguchi
- Erina Hasegawa
- Shiori Hirosawa
- Miki Kobayashi
- Hiroshi Hirosawa
- Kaede Sato
- Takako Fukazawa
- Yuka Maruyama
- Toshiaki Yoshida
View Affiliations

Affiliations: Department of Nursing, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950‑1104, Japan, Education Team of Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950‑1104, Japan, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, Niigata, Niigata 950‑1104, Japan
Published online on: November 10, 2017 https://doi.org/10.3892/etm.2017.5488
Pages: 970-976

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interferon‑free direct acting antiviral agent regimens for chronic hepatitis C (CHC) have been developed. These regimens have shown a high rate of sustained virologic response (SVR), and a reduction in side effects during treatment is also anticipated. However, the impact of the regimens on health‑related quality of life (HRQOL) and side effects during treatment is not fully understood. The purpose of the present study was to evaluate HRQOL in the clinical course of patients with CHC receiving daclatasvir/asunaprevir (DCV/ASV) therapy using the Short Form‑36 (SF‑36) method. Twenty‑eight patients with CHC receiving DCV/ASV therapy were analyzed in the present study, and HRQOL was measured by SF‑36. Patients were asked to fill out the SF‑36 prior to therapy (baseline), following 12 weeks of therapy, at the end of treatment and at SVR week 24 (SVR24) to evaluate HRQOL. Laboratory data were also investigated during the same period, and associations between these results and SF‑36 were investigated. Aspartate aminotransferase, alanine aminotransferase, serum albumin, α‑fetoprotein, platelet counts and Fibrosis (Fib)‑4 index were all significantly improved at each time point when compared with baseline. With regard to alterations in HRQOL during therapy, the ≥70‑year‑old group displayed a significantly greater improvement in physical functioning during the period between baseline and 12 weeks when compared with the <70‑year‑old group. In the analysis of the SF‑36 differences within each group, general health improved significantly in the ≥70‑year‑old group, as well as albumin levels. In addition, Fib‑4‑index significantly improved at all time points (12 and 24 weeks, and SVR24) when compared with baseline in the ≥70‑year‑old group. Therefore, DCV/ASV therapy may improve HRQOL and hepatic functional reserve, particularly in elderly patients.

View Figures

View References

1	Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW and Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 244:359–362. 1989. View Article : Google Scholar : PubMed/NCBI
2	Hajarizadeh B, Grebely J and Dore GJ: Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 10:553–562. 2013. View Article : Google Scholar : PubMed/NCBI
3	Gower E, Estes C, Hindman S, Razavi-Shearer K and Razavi H: Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 61 1 Suppl:S45–S57. 2014. View Article : Google Scholar : PubMed/NCBI
4	Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 17:107–115. 2011. View Article : Google Scholar : PubMed/NCBI
5	Thein HH, Yi Q, Dore GJ and Krahn MD: Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology. 48:418–431. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tyagi I and Koirala J: Hepatitis C. StatPearls Publishing; Treasure Island, FL: 2017
7	Zhu GQ, Zou ZL, Zheng JN, Chen DZ, Zou TT, Shi KQ and Zheng MH: Systematic review and network meta-analysis of randomized controlled trials: Comparative effectiveness and safety of direct-acting antiviral agents for treatment-naive hepatitis C Genotype 1. Medicine (Baltimore). 95:e30042016. View Article : Google Scholar : PubMed/NCBI
8	Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, et al: Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2). Hepatology. 64:360–369. 2016. View Article : Google Scholar : PubMed/NCBI
9	Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis. 15:645–653. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, et al: Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected japanese patients with or without cirrhosis. Hepatology. 62:1037–1046. 2015. View Article : Google Scholar : PubMed/NCBI
11	Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA and Kumada H: Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis c virus-infected patients. Hepatology. 61:1523–1532. 2015. View Article : Google Scholar : PubMed/NCBI
12	Younossi ZM, Stepanova M, Nader F, Lam B and Hunt S: The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: A study of health-related quality of life. Aliment Pharmacol Ther. 42:286–295. 2015. View Article : Google Scholar : PubMed/NCBI
13	Suzuki M, Ishikawa T, Sakuma A, Abe S, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, et al: Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitisis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Exp Ther Med. 12:3353–3358. 2016. View Article : Google Scholar : PubMed/NCBI
14	Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, et al: Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 150:419–429. 2016. View Article : Google Scholar : PubMed/NCBI
15	Younossi ZM, Stepanova M, Chan HL, Lee MH, Yu ML, Dan YY, Choi MS and Henry L: Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (Baltimore). 95:e27022016. View Article : Google Scholar : PubMed/NCBI
16	Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M and Hunt S: Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. Health Qual Life Outcomes. 15:252017. View Article : Google Scholar : PubMed/NCBI
17	Youssef NF, El Kassas M, Farag A and Shepherd A: Health-related quality of life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: A prospective observational study in Egypt. BMC Gastroenterol. 17:182017. View Article : Google Scholar : PubMed/NCBI
18	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
19	Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD and Murray CJ: Healthy life expectancy for 187 countries, 1990–2010: A systematic analysis for the Global Burden Disease Study 2010. Lancet. 380:2144–2162. 2012. View Article : Google Scholar : PubMed/NCBI
20	Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S and Kanwal F: Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology. 41:790–800. 2005. View Article : Google Scholar : PubMed/NCBI
21	Svirtlih N, Pavic S, Terzic D, Delic D, Simonovic J, Gvazdenovic E and Boricic I: Reduced quality of life in patients with chronic viral liver disease as assessed by SF12 questionnaire. J Gastrointest Liver Dis. 17:405–409. 2008.
22	Tao T, Jiang X, Chen Y and Song Y: Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: A meta-analysis. Int J Infect Dis. 55:56–71. 2017. View Article : Google Scholar : PubMed/NCBI
23	Bunchorntavakul C and Reddy KR: Review article: The efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 42:258–272. 2015. View Article : Google Scholar : PubMed/NCBI
24	Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014. View Article : Google Scholar : PubMed/NCBI
25	Santos PR and Franco Sansigolo Kerr LR: Clinical and laboratory variables associated with quality of life in Brazilian haemodialysis patients: A single-centre study. Rev Med Chil. 136:1264–1271. 2008. View Article : Google Scholar : PubMed/NCBI
26	Parkash O, Iqbal R, Jafri F, Azam I and Jafri W: Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes. 5:4462012. View Article : Google Scholar : PubMed/NCBI
27	Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, et al: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 43:1317–1325. 2006. View Article : Google Scholar : PubMed/NCBI
28	Zhang DY and Friedman SL: Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 56:769–775. 2012. View Article : Google Scholar : PubMed/NCBI
29	Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, et al: NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 52:845–854. 2017. View Article : Google Scholar : PubMed/NCBI
30	Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, et al: Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res. Apr 29–2017.(Epub ahead of print). View Article : Google Scholar